259 Appendices A normal individuals. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):410-422. doi: 10.1007/s00259-022-05958-8. 15. Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jögi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR Jr, Hansson O. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022 Nov;28(11):2381-2387. doi: 10.1038/s41591-022-02049-x. 16. Wisse LE, Visser D, Ter Braak TJ, Bakkali A, Struys EA, Morrison CD, van der Knaap MS, Abbink TEM. Isocaloric low protein diet in a mouse model for vanishing white matter does not impact ISR deregulation in brain, but reveals ISR deregulation in liver. Nutr Neurosci. 2022 Jun;25(6):1219-1230. doi: 10.1080/1028415X.2020.1846356. 17. Wolters EE, Papma JM, Verfaillie SCJ, Visser D, Weltings E, Groot C, van der Ende EL, Giannini LAA, Tuncel H, Timmers T, Boellaard R, Yaqub M, van Assema DME, Kuijper DA, Segbers M, Rozemuller AJM, Barkhof F, Windhorst AD, van der Flier WM, Pijnenburg YAL, Scheltens P, van Berckel BNM, van Swieten JC, Ossenkoppele R, Seelaar H. [18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology. 2021 Sep 7;97(10):e1017-e1030. doi: 10.1212/WNL.0000000000012448. 18. Singleton E, Hansson O, Pijnenburg YAL, La Joie R, Mantyh WG, Tideman P, Stomrud E, Leuzy A, Johansson M, Strandberg O, Smith R, Berendrecht E, Miller BL, Iaccarino L, Edwards L, Strom A, Wolters EE, Coomans E, Visser D, Golla SSV, Tuncel H, Bouwman F, Van Swieten JC, Papma JM, van Berckel B, Scheltens P, Dijkstra AA, Rabinovici GD, Ossenkoppele R. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2021 Apr 13;92(8):872-80. doi: 10.1136/jnnp-2020-325497. 19. Timmers T, Ossenkoppele R, Visser D, Tuncel H, Wolters EE, Verfaillie SCJ, van der Flier WM, Boellaard R, Golla SSV, van Berckel BNM. Test-retest repeatability of [18F] Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2020 Dec;40(12):2464-2474. doi: 10.1177/0271678X19879226. 20. Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2866-2878. doi: 10.1007/s00259-020-04758-2. 21. Wolters EE, Ossenkoppele R, Golla SSV, Verfaillie SCJ, Timmers T, Visser D, Tuncel H, Coomans EM, Windhorst AD, Scheltens P, van der Flier WM, Boellaard R, van Berckel BNM. Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of
RkJQdWJsaXNoZXIy MjY0ODMw